相似文献
1
SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice.SGLT2抑制剂独立于SGLT2发挥作用，对小鼠射血分数降低的心力衰竭有益。
Circ Res. 2024 Aug 16;135(5):632-634. doi: 10.1161/CIRCRESAHA.124.324823. Epub 2024 Jul 23.
2
The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in Patients With Heart Failure.钠-葡萄糖协同转运蛋白 2 抑制剂治疗对心力衰竭患者内皮祖细胞功能的影响。
J Cardiovasc Pharmacol. 2024 Aug 1;84(2):220-226. doi: 10.1097/FJC.0000000000001581.
3
The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对心脏功能成像标志物的影响：一项系统评价和荟萃分析。
Pharmacol Res. 2022 Jun;180:106243. doi: 10.1016/j.phrs.2022.106243. Epub 2022 May 4.
4
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.恩格列净通过抑制 NHE1-NO 通路来预防心力衰竭，与 SGLT2 无关。
Basic Res Cardiol. 2024 Oct;119(5):751-772. doi: 10.1007/s00395-024-01067-9. Epub 2024 Jul 24.
5
Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.钠-葡萄糖协同转运蛋白 2 抑制剂对射血分数降低的心力衰竭患者肺动脉僵硬度和右心室功能的影响。
Medicina (Kaunas). 2022 Aug 19;58(8):1128. doi: 10.3390/medicina58081128.
6
Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues.超越酮症：对SGLT2抑制剂益处潜在机制的探索仍在继续。
J Clin Invest. 2024 Dec 16;134(24):e187097. doi: 10.1172/JCI187097.
7
Central SGLT2 mediate sympathoexcitation in hypertensive heart failure via attenuating subfornical organ endothelial cGAS ubiquitination to amplify neuroinflammation: Molecular mechanism behind sympatholytic effect of Empagliflozin.中枢SGLT2通过减弱穹窿下器内皮细胞cGAS泛素化以放大神经炎症介导高血压性心力衰竭中的交感神经兴奋：恩格列净交感神经抑制作用背后的分子机制
Int Immunopharmacol. 2025 Jan 3;145:113711. doi: 10.1016/j.intimp.2024.113711. Epub 2024 Dec 7.
8
Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.射血分数保留和轻度降低的心衰的最佳药物治疗：一项荟萃分析。
JAMA Netw Open. 2022 Sep 1;5(9):e2231963. doi: 10.1001/jamanetworkopen.2022.31963.
9
The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂、肾素-血管紧张素系统（RAS）抑制剂和血管紧张素受体拮抗剂（ARN）抑制剂对心力衰竭的心血管影响。
ESC Heart Fail. 2023 Apr;10(2):1314-1325. doi: 10.1002/ehf2.14298. Epub 2023 Feb 1.
10
Evaluation of the Effects of the Sodium-Glucose Cotransporter 2 Inhibitors and Sacubitril/Valsartan Combined Therapy in Patients with HFrEF: An Echocardiographic Study.钠-葡萄糖协同转运蛋白2抑制剂与沙库巴曲缬沙坦联合治疗对射血分数降低的心力衰竭患者的影响评估：一项超声心动图研究
Int J Mol Sci. 2025 Jun 12;26(12):5651. doi: 10.3390/ijms26125651.
引用本文的文献
1
Integrated Systems Biology Identifies Disruptions in Mitochondrial Function and Metabolism as Key Contributors to HFpEF.整合系统生物学确定线粒体功能和代谢紊乱是射血分数保留的心力衰竭的关键促成因素。
JACC Basic Transl Sci. 2025 Aug 15;10(9):101334. doi: 10.1016/j.jacbts.2025.101334.
2
Inhibition of the Na-glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4 T cells.抑制钠-葡萄糖转运蛋白SGLT2可减少活化的人CD4 T细胞对葡萄糖的摄取及γ干扰素的释放。
Front Immunol. 2025 Jun 17;16:1576216. doi: 10.3389/fimmu.2025.1576216. eCollection 2025.
3
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.心力衰竭中的心脏中间代谢：底物利用、信号作用及治疗靶点。
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01166-7.
4
Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction.恩格列净可恢复急性心肌梗死时的心脏代谢并抑制免疫激活。
Atherosclerosis. 2025 Aug;407:120404. doi: 10.1016/j.atherosclerosis.2025.120404. Epub 2025 Jun 12.
5
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.糖尿病驱动的动脉粥样硬化：最新机制见解与新型治疗策略
Int J Mol Sci. 2025 Feb 28;26(5):2196. doi: 10.3390/ijms26052196.
6
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure.对SGLT2表达的单细胞转录组分析支持了恩格列净对心力衰竭心脏保护作用的间接或脱靶作用。
Sci Rep. 2025 Mar 10;15(1):8265. doi: 10.1038/s41598-025-93144-9.
7
Pantothenate Kinase 1 Identified as a Direct Target of SGLT2 Inhibitors in the Heart.泛酸激酶1被确定为心脏中SGLT2抑制剂的直接靶点。
J Cardiovasc Pharmacol. 2025 May 1;85(5):305-307. doi: 10.1097/FJC.0000000000001689.
8
Empagliflozin to Prevent Doxorubicin Cardiotoxicity.恩格列净预防阿霉素心脏毒性
JACC CardioOncol. 2025 Feb;7(2):185-187. doi: 10.1016/j.jaccao.2025.01.005.
9
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.糖尿病中的动脉粥样硬化：新机制及基于机制的治疗方法。
Nat Rev Cardiol. 2025 Jan 13. doi: 10.1038/s41569-024-01115-w.
10
Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues.超越酮症：对SGLT2抑制剂益处潜在机制的探索仍在继续。
J Clin Invest. 2024 Dec 16;134(24):e187097. doi: 10.1172/JCI187097.
本文引用的文献
1
Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2.达格列净通过抑制巨噬细胞介导体液炎症来预防小鼠慢性心力衰竭，与 SGLT2 无关。
Cell Rep Med. 2023 Dec 19;4(12):101334. doi: 10.1016/j.xcrm.2023.101334.
2
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.钠葡萄糖协同转运蛋白2抑制剂恩格列净可独立于钠葡萄糖协同转运蛋白2减少梗死面积。
Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688.
3
SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.钠-葡萄糖协同转运蛋白2抑制剂：从降糖药到全方位心力衰竭治疗药物
Circulation. 2022 Jul 26;146(4):299-302. doi: 10.1161/CIRCULATIONAHA.122.060348. Epub 2022 Jul 25.
4
Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure.新型左心室压力超负荷和梗死小鼠模型，可导致可预测的心室重塑并进展为心力衰竭。
Clin Exp Pharmacol Physiol. 2015 Jan;42(1):33-40. doi: 10.1111/1440-1681.12318.
5
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.达格列净，一种选择性钠-葡萄糖共转运蛋白 2 抑制剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3.
Zotero 插件